Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 4/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109487 | 1.00 | SIGMAR1 (0.43) | SIGMAR1GRM2HCRTR1HCRTR2 | |
| SCHEMBL5112230 | 1.00 | SIGMAR1 (0.43) | SIGMAR1GRM2HCRTR1HCRTR2 | |
| SCHEMBL340210 | 0.92 | SIGMAR1 (0.43) | SIGMAR1GRM2HCRTR1HCRTR2 | |
| SCHEMBL341707 | 0.91 | SIGMAR1 (0.41) | SIGMAR1GRM2HCRTR1HCRTR2 | |
| SCHEMBL342253 | 0.91 | SIGMAR1 (0.46) | SIGMAR1GRM2 | |
| SCHEMBL342890 | 0.89 | POLB (0.41) | GRM2HCRTR1HCRTR2 | |
| SCHEMBL341722 | 0.88 | HCRTR1 (0.41) | HCRTR1HCRTR2 | |
| SCHEMBL342354 | 0.88 | HPGD (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL340590 | 0.87 | MEN1 (0.45) | HCRTR2 | |
| SCHEMBL340821 | 0.87 | SIGMAR1 (0.40) | SIGMAR1GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | claimed |
| US-20120183600-A1 | NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS | CHEN CHIEN-HUNG (US) | 2012-07-19 | — | — | US | claimed |
| EP-1461339-B1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARM INC (US) | 2010-04-28 | — | — | EP | claimed |
| US-20090131418-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARAMCEUTICALS, INC. (US) | 2009-05-21 | — | — | US | claimed |
| US-7402590-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2008-07-22 | — | — | US | claimed |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS (US) | 2007-07-12 | — | — | US | claimed |
| US-6911452-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2005-06-28 | — | — | US | claimed |
| EP-1461339-A2 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | Acadia Pharmaceuticals Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2003-09-04 | — | — | US | claimed |
| WO-2003057698-A2 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | claimed |
| US-20150231126-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARM INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150231126-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | ACADIA PHARM INC (US) | 2015-08-20 | — | — | US | disclosed |
| US-9050343-B2 | Combination of pimavanserin and risperidone for the treatment of psychosis | ACADIA PHARMACEUTICALS INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050343-B2 | Combination of pimavanserin and risperidone for the treatment of psychosis | ACADIA PHARMACEUTICALS INC. (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140350064-A1 | PHARMACEUTICAL COMPOSITION COMPRISING AN AMPK ACTIVATOR AND A SEROTONERGIC AGENT AND METHODS OF USE THEREOF | ALS MOUNTAIN LLC | 2014-11-27 | — | — | US | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-6911452-B2 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. (US) | 2005-06-28 | — | — | US | disclosed |
| EP-1461339-A2 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | Acadia Pharmaceuticals Inc. (US) | 2004-09-29 | — | — | EP | disclosed |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | ACADIA PHARMACEUTICALS INC. | 2003-09-04 | — | — | US | disclosed |
| WO-2003057698-A2 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | ACADIA PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150231126-A1 | COMBINATIONS OF 5-HT2A INVERSE AGONISTS AND ANTAGONISTS WITH ANTIPSYCHOTICS | HTR2A, HTR3A, HTR1A | SIGMAR1 314/4885GRM2 105/4885HCRTR1 212/4885 |
| US-20090131418-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | MAOA, MAOB, HTR5A | SIGMAR1 103/4885GRM2 260/4885HCRTR1 22/4885 |
| US-20030166928-A1 | Spiroazacyclic compounds as monoamine receptor modulators | MAOA, MAOB, HTR5A | SIGMAR1 103/4885GRM2 260/4885HCRTR1 22/4885 |
| US-20070161621-A1 | SPIROAZACYCLIC COMPOUNDS AS MONOAMINE RECEPTOR MODULATORS | MAOA, MAOB, HTR5A | SIGMAR1 103/4885GRM2 260/4885HCRTR1 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.